Cathepsin K Inhibitors – PharmaLive

Stock Pops as Medivir Decides to Split into Two Companies

Biotech, Business, Cathepsin K Inhibitors, Clinical Trials, HCV nucleotide analogue NS5B polymerase inhibitors, Health, Hepatitis C, Hepatocellular Carcinoma, HIV, Nasdaq First North, R&D, Respiratory Syncytial Virus, Splits, Stocks

Medivir AB announced that it plans to split up into two independent companies.

August 31, 2016/by BioSpace